Cadus Pharmaceutical Corp. (KDUS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS)

KDUS 1.600

0.0%

Jul 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MCsweet who wrote (1596)	10/4/2008 12:40:43 PM
From: scaram(o)uche	Read Replies (3) of 1833

They've passed on two severe liquidity crunches, where cash was in great demand. Blitz is fibbing to Tomato. Icahn isn't interested in selling or merging the company, as DD would disclose the fraud which involves OSIP, Cadus and Solvay projects. That's the only reasonable explanation. I simply don't hold enough shares to care much. We were once going to help someone in this thread (you?) draft wording for inclusion in def 14a. We should do it. Solvay is sincere about developing SLV320, that's obvious. The royalty issue is therefore still alive, and even a fraction of one percent of the CHF market would be huge revenue to Cadus (in perspective of market cap). Shareholders should not lose sight of compelling weird bevavior from Goddard.... he stopped touting the Solvay collaboration BEFORE Tarceva was returned, at a time when the OSIP business plan was weak. Shortly thereafter, Prosidion was born and inherited the GPCR work at OSIP. And, on that note, we should also not lose sight of the GPR119 agonist, PSN821, and potential CONTRACTUAL ties to Cadus.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next